Pathophysiology of meningiomas

Seminars in Neurosurgery

Volumn 14, Issue 3, 2003, Pages 169-185

  Ragel, Brian ^a   Jensen, Randy L ^a,b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Histology; Meningioma tumorigenesis; Prognosis; Tumor grading

Indexed keywords

ALPHA2B INTERFERON; ANTIGESTAGEN; CYTOKINE; DOPAMINE; ENDOTHELIN; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; GESTAGEN; GESTRINONE; GROWTH FACTOR; INTERLEUKIN 6; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NEUROFIBROMATOSIS TYPE 2 PROTEIN; ONAPRISTONE; PEPTIDE HORMONE; SEX HORMONE; SOMATOMEDIN; SOMATOSTATIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER GRADING; CANCER RECURRENCE; CARCINOGENESIS; CHROMOSOME 22; CHROMOSOME ABERRATION; CLINICAL TRIAL; FLU LIKE SYNDROME; GENE DELETION; HISTOPATHOLOGY; HUMAN; LABELING INDEX; LEUKOPENIA; MALIGNANT MENINGIOMA; MENINGIOMA; NONHUMAN; PROGNOSIS; REVIEW; TUMOR GROWTH;

EID: 2442695421     PISSN: 15268012     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-817734     Document Type: Review

References (251)

1. Al-Rodhan RF, Laws ER. The history of intracranial meningiomas. In: Al-Mefty O, ed. Meningiomas. New York: Raven Press; 1991:1-6
2. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999;42:109-116
3. Catala M. Embryonic and fetal development of structures associated with the cerebro-spinal fluid in man and other species. Part I: The ventricular system, meninges and choroid plexuses. Arch Anat Cytol Pathol 1998;46:153-169
4. Burger PC, Scheithauer BW, Vogel FS. Surgical Pathology of the Nervous System and Its Coverings. 4th ed. Philadelphia: Churchill Livingstone; 2002:49-71
5. Osborn AG. Diagnostic Neuroradiology. St. Louis: Mosby; 1994:584-601
6. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993;33:955-963
7. Gonzales MF. Classification of brain tumors. In: Kaye AH, Laws ER, eds. Brain Tumors. 1st ed: Edinburgh: Churchill Livingstone; 1995:675
8. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System. Lyon: IARC Press; 2000:175-189
9. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233-242
10. Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am J Surg Pathol 2001; 25:472-478
11. Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002;94:1538-1547
12. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Pract 2000;196:483-488
13. Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance. Arch Pathol Lab Med 2002;126:1079-1086
14. Kamei Y, Watanabe M, Nakayama T, Kanamaru K, Waga S, Shiraishi T. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neurooncol 2000;46:205-213
15. Abramovich CM, Prayson RA. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome. Am J Clin Pathol 2000;114:84-92
16. Bostrom J, Meyer-Puttlitz B, Wolter M, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 2001;159:661-669
17. Comtesse N, Heckel D, Racz A, Brass N, Glass B, Meese E. Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping. Clin Cancer Res 1999;5:3560-3568
18. Weisberg S, Ashkenazi E, Israel Z, et al. Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation. Am J Pathol 2001; 159:1193-1197
19. Kilic T, Bayri Y, Ozduman K, et al. Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape. Neurosurgery 2002;51:183-192; discussion 192-193
20. Griffin CA, Hruban RH, Long PP, et al. Chromosome abnormalities in meningeal neoplasms: do they correlate with histology? Cancer Genet Cytogenet 1994;78:46-52
21. Bolger GB, Stamberg J, Kirsch IR, Hollis GF, Schwarz DF, Thomas GH. Chromosome translocation t(14;22) and oncogene (c-sis) variant in a pedigree with familial meningioma. N Engl J Med 1985;312:564-567
22. Awad IA, Kalfas I, Hahn JF, Little JR. Intracranial meningiomas in the aged: surgical outcome in the era of computed tomography. Neurosurgery 1989;24:557-560
23. Cogen PH, Daneshvar L, Bowcock AM, Metzger AK, Cavalli-Sforza LL. Loss of heterozygosity for chromosome 22 DNA sequences in human meningioma. Cancer Genet Cytogenet 1991;53:271-277
24. Casalone R, Minelli E, Granata P, Giudici A. Pseudodicentric isochromosome(22) in meningiomas. Cancer Genet Cytogenet 1990;45:273-275
25. Dumanski JP, Carlbom E, Collins VP, Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci U S A 1987;84:9275-9279
26. Lekanne Deprez RH, Riegman PH, van Drunen E, et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54:224-235
27. Meese E, Blin N, Zang KD. Loss of heterozygosity and the origin of meningioma. Hum Genet 1987;77:349-351
28. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A 1987;84:5419-5423
29. Zang KD, Singer H. Chromosomal constitution of meningiomas. Nature 1967;216:84-85
30. Zankl H, Zang KD. Correlations between clinical and cytogenetical data in 180 human meningiomas. Cancer Genet Cytogenet 1980;1:351-356.
31. Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 2001;93:207-220
32. Lekanne Deprez RH, Bianchi AB, Groen NA, et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994;54:1022-1029
33. Leon SP, Zhu J, Black PM. Genetic aberrations in human brain tumors. Neurosurgery 1994;34:708-722
34. Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. Cancer Genet Cytogenet 1990;47:141-154
35. Wolff RK, Frazer KA, Jackler RK, Lanser MJ, Pitts LH, Cox DR. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors. Am J Hum Genet 1992; 51:478-485
36. Merel P, Hoang-Xuan K, Sanson M, et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 1995;13:211-216
37. Papi L, De Vitis LR, Vitelli F, et al. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 1995;95:347-351
38. Ng HK, Lau KM, Tse JY, et al. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 1995;37:764-773
39. Wellenreuther R, Kraus JA, Lenartz D, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995;146:827-832
40. Ikeda K, Saeki Y. Gonzalez-Agosti C, Ramesh V, Chiocca EA. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 1999;91:85-92
41. Dirven CM, Grill J, Lamfers ML, et al. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. J Neurosurg 2002;97:441-449
42. Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW. Golubi M. Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery 1997;40:578-587
43. Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16:1060-1065
44. Akagi K, Kurahashi H, Arita N, et al. Deletion mapping of the long arm of chromosome 22 in human meningiomas. Int J Cancer 1995;60:178-182
45. Lekanne Deprez RH, Groen NA, van Biezen NA, et al. A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene. Am J Hum Genet 1991;48: 783-790
46. Lekanne Deprez RH, Groen NA, Louz D, et al. Constitutional DNA-level aberrations in chromosome 22 in a patient with multiple meningiomas. Genes Chromosomes Cancer 1994;9:124-128
47. Dumanski JP, Rouleau GA, Nordenskjold M, Collins VP. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 1990;50:5863-5867
48. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 1993;43:2096-2098
49. Schneider G, Lutz S, Henn W, Zang KD, Blin N. Search for putative suppressor genes in meningioma: significance of chromosome 22. Hum Genet 1992;88:579-582
50. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-184
51. Ruttledge MH, Xie YG, Han FY, et al. Deletions on chromosome 22 in sporadic meningioma. Genes Chromosomes Cancer 1994;10:122-130
52. Bello MJ, de Campos JM, Kusak ME, et al. Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 1994;9:296-298
53. Steudel WI, Feld R, Henn W, Zang KD. Correlation between cytogenetic and clinical findings in 215 human meningiomas. Arch Neurochir Suppl (Wien) 1996;65: 73-76
54. Muller P, Henn W, Niedermayer I, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res 1999;5:3569-3577
55. Henn W, Cremerius U, Heide G, et al. Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas. Cancer Genet Cytogenet 1995;79:144-148
56. Ketter R, Henn W, Niedermayer I, et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg 2001;95:601-607
57. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001;60:628-636
58. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Barcia-Salorio JL, Llombart-Bosch A. Loss of 1p in recurrent meningiomas. a comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization. Cancer Genet Cytogenet 2001;125:119-124
59. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995;55:4696-4701
60. Schneider BF, Shashi V, von Kap-herr C, Golden WL. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. Cancer Genet Cytogenet 1995;85:101-104
61. Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59: 872-879
62. Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-1500
63. Prempree T, Amornmarn R, Faillace WJ, Arce CA, Nguyen TQ. 1;19 translocation in human meningioma. Cancer 1993;71:2306-2311
64. Vagner Capodano AM, Grisoli F, Gambarelli D, Sedan R, Pellet W, De Victor B. Correlation between cytogenetic and histopathological findings in 75 human meningiomas. Neurosurgery 1993;32:892-900; discussion 900
65. Al Saadi A, Latimer F, Madercic M, Robbins T. Cytogenetic-studies of human brain tumors and their clinical significance. II. Meningioma. Cancer Genet Cytogenet 1987;26:127-141
66. Katsuyama J, Papenhausen PR, Herz F, Gazivoda P, Hirano A, Koss LG. Chromosome abnormalities in meningiomas. Cancer Genet Cytogenet 1986;22:63-68
67. Westphal M, Hansel M, Kunzmann R, Holzel F, Herrmann HD. Spectrum of karyotypic aberrations in cultured human meningiomas. Cytogenet Cell Genet 1989;52:45-49
68. Bigner SH, Wong AJ, Mark J, et al. Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet 1987;29:165-170
69. Mark J. Chromosomal abnormalities and their specificity in human neoplasms: an assessment of recent observations by banding techniques. Adv Cancer Res 1977;24:165-222
70. Lopez-Gines C, Cerda-Nicolas M, Barcia-Salorio JL, Llombart-Bosch A. Cytogenetical findings of recurrent meningiomas. A study of 10 tumors. Cancer Genet Cytogenet 1995;85:113-117
71. Pykett MJ, Murphy M, Harnish PR, George DL. Identification of a microsatellite instability phenotype in meningiomas. Cancer Res 1994;54:6340-6343
72. Cushing J, Eisenhardt L. Meningiomas arising from the tuberculum sella. Arch Ophthalmol 1929;1:1-41
73. Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurochem 1958;21:89-91
74. Goldstein PJ, Rosenberg S, Smith RW. Maternal death and brain tumor: case report. Am J Obstet Gynecol 1972;112: 297-298
75. Hagedoorne A. The chiasmal syndrome and retrobulbar neuritis in pregnancy. Am J Ophthalmol 1937;20:690-699
76. Weyand AS, Villemure J, Kelly PA. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas. Cancer Res 1986;46:2545-2550
77. Mehta D, Khatib R, Patel S. Carcinoma of the breast and meningioma. Association and management. Cancer 1983; 51:1937-1940
78. Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975;25:705-712
79. Bellur SN, Chandra V, Anderson RJ. Association of meningiomas with obesity. Ann Neurol 1983;13:346-347
80. Donnell MS, Meyer GA, Donegan WL. Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 1979;50: 499-502
81. Magdelenat H, Pertuiset BF, Poisson M, et al. Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases. Acta Neurochir (Wien) 1982;64:199-213
82. Martuza RL, Miller DC, MacLaughlin DT. Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas. J Neurosurg 1985;62:750-756
83. Poisson M. Sex steroid receptors in human meningiomas. Clin Neuropharmacol 1984;7:320-324
84. Tilzer LL, Plapp FV, Evans JP, Stone D, Alward K. Steroid receptor proteins in human meningiomas. Cancer 1982;49: 633-636
85. Markwalder TM, Zava DT, Goldhirsch A, Markwalder RV. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features. Surg Neurol 1983; 20:42-47
86. Piantelli M, Rinelli A, Macri E, et al. Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas. Cancer 1993;71:193-198
87. Blankenstein MA, Blaauw G, Lamberts SW. Progestin and estrogen receptors in human meningioma. Clin Neuropharmacol 1984;7:363-367
88. Moguilewsky M, Pertuiset BF, Verzat C, Philibert D, Philippon J, Poisson M. Cytosolic and nuclear sex steroid receptors in meningioma. Clin Neuropharmacol 1984;7:375-381
89. Hayward E, Whitwell H, Paul KS, Barnes DM. Steroid receptors in human meningioma. Clin Neuropharmacol 1984; 7:351-356
90. Cahill DW, Bashirelahi N, Solomon LW, Dalton T, Salcman M, Ducker TB. Estrogen and progesterone receptors in meningiomas. J Neurosurg 1984;60:985-993
91. Courriere P, Tremoulet M, Eche N, Armand JP. Hormonal steroid receptors in intracranial tumours and their relevance in hormone therapy. Eur J Cancer Clin Oncol 1985;21:711-714
92. Blaauw G, Blankenstein MA, Lamberts SW. Sex steroid receptors in human meningiomas. Acta Neurochir (Wien) 1986;79:42-47
93. Blankenstein MA, van der Meulen-Dijk C, Thijssen JH. Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods. Clin Chim Acta 1987;165:189-195
94. Benzel EC, Gelder FB. Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas. Neurosurgery 1988;23:169-174
95. Koehorst SG, Jacobs HM, Tilanus MG, Bouwens AG, Thijssen JH, Blankenstein MA. Aberrant oestrogen receptor species in human meningioma tissue. J Steroid Biochem Mol Biol 1992;43:57-61
96. Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 1993;33:212-217; discussion 217-218
97. Carroll RS, Glowacka D, Dashner K, Black PM. Progesterone receptor expression in meningiomas. Cancer Res 1993; 53:1312-1316
98. Ironside JW, Battersby RD, Dangerfield VJ, Parsons MA, Timperley WR, Underwood JC. Cryostat section assay of oestrogen and progesterone receptors in meningiomas: a clinicopathological study. J Clin Pathol 1986;39:44-50
99. Lesch KP, Fahlbusch R. Simultaneous estradiol and progesterone receptor analysis in meningiomas. Surg Neurol 1986; 26:257-263
100. Lesch KP, Engl HG, Gross S. Androgen receptor binding activity in meningiomas. Surg Neurol 1987;28:176-180
101. Lesch KP, Engl HG, Schott W, Gross S. Immunoreactive estrogen receptor protein in meningiomas: comparison with the androgen receptor and progesterone receptor binding activity. Zentralbl Neurochir 1987;48:124-134
102. Schrell UM, Adams EF, Fahlbusch R, et al. Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. J Neurosurg 1990;73:743-749
103. Piquer J, Cerda M, Lluch A, Barcia-Salorio JL, Garcia-Conde J. Correlations of female steroid hormone receptors with histologic features in meningiomas. Acta Neurochir (Wien) 1991;110:38-43
104. Meixensberger J, Caffier H, Naumann M, Hofmann E. Sex hormone binding and peritumoural oedema in meningiomas: is there a correlation? Acta Neurochir (Wien) 1992; 115:98-102
105. Perrot-Applanat M, Groyer-Picard MT, Kujas M. Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir (Wien) 1992;115:20-30
106. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 1993;78:456-462
107. Verhagen A, Go KG, Visser GM, Blankenstein MA, Vaalburg W. The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: its relevance to expression of progesterone receptors in meningiomas. Br J Neurosurg 1995;9:47-50
108. Bouillot P, Pellissier JF, Devictor B, et al. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data. J Neurosurg 1994;81:765-773
109. Zava DT, Markwalder TM, Markwalder RV. Biological expression of steroid hormone receptors in primary meningioma cells in monolayer culture. Clin Neuropharmacol 1984;7:382-388
110. Jay JR, MacLaughlin DT, Riley KR, Martuza RL. Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 1985;62:757-762
111. Olson JJ, Beck DW, Schlechte J, Loh PM. Hormonal manipulation of meningiomas in vitro. J Neurosurg 1986;65:99-107
112. Weisman AS, Villemure JG, Kelly PA. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas. Cancer Res 1986;46:2545-2550
113. Waelti ER, Markwalder TM. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture. Surg Neurol 1989;31:96-100
114. Grunberg SM, Daniels AM, Muensch H, et al. Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay. J Neurosurg 1987;66: 405-408
115. Adams EF, Schrell UM, Fahlbusch R, Thierauf P. Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas. J Neurosurg 1990;73: 750-755
116. Olson JJ, Beck DW, Schlechte JA, Loh PM. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 1987;66:584-587
117. Koper JW, Foekens JA, Braakman R, Lamberts SW. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res 1990;50:2604-2607
118. Schrell UM, Nomikos P, Schrauzer T, et al. Hormonal dependency of cerebral meningiomas. Acta Neurochir Suppl (Wien) 1996;65:54-57
119. Markwalder TM, Seiler RW. Chronic subdural hematomas: to drain or not to drain? Neurosurgery 1985;16:185-188
120. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993;15:75-77
121. Markwalder TM, Gerber HA, Waelti E, Schaffner T, Markwalder RV. Hormonotherapy of meningiomas with medroxyprogesterone acetate. Immunohistochemical demonstration of the effect of medroxyprogesterone acetate on growth fractions of meningioma cells using the monoclonal antibody Ki-67. Surg Neurol 1988;30:97-101
122. Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, Troupp H. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien) 1986;80:35-41
123. Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 1990;8:61-65
124. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-866
125. Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991;73:187-191
126. Lamberts SW, Koper JW, Reubi JC, Krenning EP. Endocrine aspects of the diagnosis and treatment of primary brain tumours. Clin Endocrinol (Oxf) 1992;37:1-10
127. Sartor O, Figg WD. Mifepristone: antineoplastic studies. Clin Obstet Gynecol 1996;39:498-505
128. Piper JG, Follett KA, Fantin A. Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. Neurosurgery 1994;34:723-725; discussion 725
129. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994;80:527-534
130. Davis C. Surgical and non-surgical treatment of symptomatic intracranial meningiomas. Br J Neurosurg 1995;9: 295-302
131. Carroll RS, Schrell UM, Zhang J, et al. Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas. Neurosurgery 1996;38:367-375
132. Jimenez-Hakim E, el Azouzi M, Black PM. The effect of prolactin and bombesin on the growth of meningioma-derived cells in monolayer culture. J Neurooncol 1993;16: 185-190
133. Boyle-Walsh E, Shenkin A, White MC, Fraser WD. Effect of glycoprotein and protein hormones on human meningioma cell proliferation in vitro. J Endocrinol 1995;145: 155-161
134. Smidt M, Kirsch I, Ratner L. Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas. J Clin Invest 1990;86:1151-1157
135. Kazumoto K, Tamura M, Hoshino H, Yuasa Y. Enhanced expression of the sis and c-myc oncogenes in human meningiomas. J Neurosurg 1990;72:786-791
136. Carstens C, Messe E, Zang KD, Blin N. Human KRAS oncogene expression in meningioma. Cancer Lett 1988;43: 37-41
137. Diedrich U, Eckermann O, Schmidtke J. Rare Ha-ras and c-mos alleles in patients with intracranial tumors. Neurology 1988;38:587-589
138. Detta A, Kenny BG, Smith C, Logan A, Hitchcock E. Correlation of proto-oncogene expression and proliferation and meningiomas. Neurosurgery 1993;33:1065-1074
139. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514
140. Zhao JF, Sharma S. Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. Cancer Genet Cytogenet 1995;83:148-154
141. Baugnet-Mahieu L, Lemaire M, Brotchi J, et al. Epidermal growth factor receptors in human tumors of the central nervous system. Anticancer Res 1990;10:1275-1280
142. Grimaux M, Magdelenat H, Poisson M, et al. [EGF receptors (epidermal growth factor) and steroid receptors in human meningioma]. Rev Neurol (Paris) 1988;144:96-103
143. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 1995;242:683-688
144. Torp SH, Helseth E, Dalen A, Unsgaard G. Expression of epidermal growth factor receptor in human meningiomas and meningeal tissue. APMIS 1992;100:797-802
145. Sanfilippo JS, Rao CV, Guarnaschelli JJ, et al. Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. Surg Gynecol Obstet 1993;177:488-496
146. Linggood RM, Hsu DW, Efird JT, Pardo FS. TGF alpha expression in meningioma-tumor progression and therapeutic response. J Neurooncol 1995;26:45-51
147. Westphal M, Herrmann HD. Epidermal growth factor-receptors on cultured human meningioma cells. Acta Neurochir (Wien) 1986;83:62-66
148. Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 1991;27:416-419
149. Di Carlo A, Mariano A, Macchia PE, Moroni MC, Beguinot L, Macchia V. Epidermal growth factor receptor in human brain tumors. J Endocrinol Invest 1992;15:31-37
150. Kitagawa N, Tsutsumi K, Niwa M, et al. Expression of a functional endothelin (ETA) receptor in human meningiomas. J Neurosurg 1994;80:723-731
151. Johnson MD, Horiba M, Winnier AR, Arteaga CL. The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. Hum Pathol 1994; 25:146-153
152. Todo T, Fahlbusch R. Accumulation of inositol phosphates in low-passage human meningioma cells following treatment with epidermal growth factor. J Neurosurg 1994; 80:890-896
153. Carroll RS, Black PM, Zhang J, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 1997;87:315-323
154. Wang JL, Nister M, Hermansson M, Westermark B, Ponten J. Expression of PDGF beta-receptors in human meningioma cells. Int J Cancer 1990;46:772-778
155. Adams EF, Todo T, Schrell UM, Thierauf P, White MC, Fahlbusch R. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. Int J Cancer 1991;49:398-402
156. Black PM, Carroll R, Glowacka D, Riley K, Dashner K. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg 1994;81:388-393
157. Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 2001; 94:293-300
158. Figarella-Branger D, Vagner-Capodano AM, Bouillot P, et al. Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis. Neuropathol Appl Neurobiol 1994;20:439-447
159. Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990;46:16-21
160. Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg 1996; 84:852-858; discussion 858-859
161. Schrell UM, Gauer S, Kiesewetter F, et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg 1995;82:600-607
162. Todo T, Adams EF, Fahlbusch R. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. J Neurosurg 1993;78: 463-469
163. Jensen RL, Lee YS, Guijrati M, Origitano TC, Wurster RD, Reichman OH. Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II. Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements. Neurosurgery 1995;37:937-946; discussion 946-947
164. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 1995;36:365-373; discussion 373-437
165. Jensen RL, Petr M, Wurster RD. Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery 2000; 46:692-702; discussion 702-703
166. Merry S, Fetherston CA, Kaye SB, Freshney RI, Plumb JA. Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil. Br J Cancer 1986;53:129-135
167. Jensen RL, Wurster RD. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surg Neurol 2001;55:275-283
168. Bowles AP, Pantazis CG, Wansley W. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study. J Neurosurg 1990;73:248-253
169. Cano-Gauci DF, Riordan JR. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 1987;36:2115-2123
170. Helson L. Calcium channel blocker enhancement of anticancer drug cytotoxicity - a review. Cancer Drug Deliv 1984; 1:353-361
171. Ince P, Appleton DR, Finney KJ, Sunter JP, Watson AJ. Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine. Br J Cancer 1986;53:137-139
172. Robinson BA, Clutterbuck RD, Millar JL, McElwain TJ. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Br J Cancer 1985;52:813-822
173. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-1972
174. Takahashi JA, Suzui H, Yasuda Y, et al. Gene expression of fibroblast growth factor receptors in the tissues of human gliomas and meningiomas. Biochem Biophys Res Commun 1991;177:1-7
175. Takahashi JA, Mori H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990;87:5710-5714
176. Ueba T, Takahashi JA, Fukumoto M, et al. Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 1994;34:221-225; discussion 225-226
177. Paulus W, Grothe C, Sensenbrenner M, et al. Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors. Acta Neuropathol (Berl) 1990;79:418-423
178. Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 1992;70: 2673-2680
179. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55:1189-1193
180. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992;50:215-222
181. Glick RP, Gettleman R, Patel K, Lakshman R, Tsibris JC. Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects. Neurosurgery 1989;24:791-797
182. Glick RP, Unterman TG, Van der Woude M, Blaydes LZ. Insulin and insulin-like growth factors in central nervous system tumors. Part V: Production of insulin-like growth factors I and II in vitro. J Neurosurg 1992;77:445-450
183. Lichtor T, Kurpakus MA, Gurney ME. Expression of insulin-like growth
184. Kurihara M, Tokunaga Y, Tsutsumi K, et al. Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma. J Neurosurg 1989;71: 538-544
185. Unterman TG, Glick RP, Waites GT, Bell SC. Production of insulin-like growth factor-binding proteins by human central nervous system tumors. Cancer Res 1991;51:3030-3036
186. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 2001;11(suppl A):S121-S123
187. Tsutsumi K, Kitagawa N, Niwa M, Himeno A, Taniyama K, Shibata S. Effect of suramin on 125I-insulin-like growth factor-I binding to human meningiomas and on proliferation of meningioma cells. J Neurosurg 1994;80:502-509
188. Lawrence JH, Tobias CA, Linfoot JA, et al. Successful treatment of acromegaly: metabolic and clinical studies in 145 patients. J Clin Endocrinol Metab 1970;31:180-198
189. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-244
190. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001;94:487-492
191. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177
192. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759
193. Garcia-Luna PP, Relimpio F, Pumar A, et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci 1993;37:237-241
194. Kunert-Radek J, Stepien H, Radek A, Lyson K, Pawlikowski M. Inhibitory effect of calcium channel blockers on proliferation of human glioma cells in vitro. Acta Neurol Scand 1989;79:166-169
195. Huisman TW, Tanghe HL, Koper JW, et al. Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. Eur J Cancer 1991;27:1453-1457
196. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SW. Somatostatin receptors in human endocrine tumors. Cancer Res 1987;47:551-558
197. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SW. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989; 134:337-344
198. Schulz S, Pauli SU, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 2000;6:1865-1874
199. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993;91:153-159
200. Hatva E, Kaipainen A, Mentula P, et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995;146:368-378
201. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56:2185-2190
202. Goldman CK, Bharara S, Palmer CA, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997;40:1269-1277
203. Kalkanis SN, Carroll RS, Zhang J, Zamani AA, Black PM. Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. J Neurosurg 1996;85:1095-1101
204. Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997;40:1016-1026
205. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000;46: 938-947; discussion 947-948
206. Shono T, Inamura T, Torisu M, Suzuki SO, Fukui M. Vascular endothelial growth factor and malignant transformation of a meningioma: case report. Neurol Res 2000;22:189-193
207. Dietzmann K, von Bossanyi P, Warich-Kirches M, Kirches E, Synowitz HJ, Firsching R. Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas. Pathol Res Pract 1997;193:503-510
208. Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 1998;96:453-462
209. Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 1997;93:109-117
210. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. Cancer 2000;89: 1102-1110
211. Bitzer M, Opitz H, Popp J, et al. Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor. Acta Neurochir (Wien) 1998; 140:333-340
212. Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 1999;85:936-944
213. Tsai JC, Hsiao YY, Teng LJ, et al. Regulation of vascular endothelial growth factor secretion in human meningioma cells. J Formos Med Assoc 1999;98:111-117
214. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613
215. Richard DE, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999;266:718-722
216. Jensen RL, Soleau S, Bhayani MK, Christiansen D. Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas. J Neurosurg 2002;97:658-667
217. Pagotto U, Arzberger T, Hopfner U, Weindl A, Stalla GK. Cellular localization of endothelin receptor mRNAs (ETA and ETB) in brain tumors and normal human brain. J Cardiovasc Pharmacol 1995;26(suppl 3):S104-S106
218. Pagotto U, Arzberger T, Hopfner U, et al. Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J Clin Invest 1995;96:2017-2025
219. Harland SP, Kuc RE, Pickard JD, Davenport AP. Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Pharmacol 1995; 26(suppl 3):S408-S411
220. Yamaga S, Tsutsumi K, Niwa M, et al. Endothelin receptor in microvessels isolated from human meningiomas: quantification with radioluminography. Cell Mol Neurobiol 1995; 15:327-340
221. Bek EL, McMillen MA. Endothelins are angiogenic. J Cardiovasc Pharmacol 2000;36:S135-S139
222. Harland SP, Kuc RE, Pickard JD, Davenport AP. Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery 1998;43:890-898; discussion 898-899
223. Nitta T, Sato K, Okumura K. Transforming growth factor (TGF)-beta like activity of intracranial meningioma and its effect on cell growth. J Neurol Sci 1991;101:19-23
224. Merlo A, Juretic A, Zuber M, et al. Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. Eur J Cancer 1993; 29A:2118-2125
225. Johnson MD, Federspiel CF, Gold LI, Moses HL. Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells. Am J Pathol 1992;141:633-642
226. Johnson MD, Gold LI, Moses HL. Evidence for transforming growth factor-beta expression in human leptomeningeal cells and transforming growth factor-beta-like activity in human cerebrospinal fluid. Lab Invest 1992;67: 360-368
227. Johnson MD, Jennings MT, Gold LI, Moses HL. Transforming growth factor-beta in neural embryogenesis and neoplasia. Hum Pathol 1993;24:457-462
228. Reubi JC, Lamberts SW, Palacios JM. Hormone dependency of meningiomas. Lancet 1989;2:1099-1100
229. Schrell UM, Nomikos P, Fahlbusch R. Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue. J Neurosurg 1992;77: 288-294
230. Todo T, Adams EF, Rafferty B, Fahlbusch R, Dingermann T, Werner H. Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth. J Neurosurg 1994;81:394-401
231. Levy EI, Paino JE, Sarin PS, et al. Enzyme-linked immunosorbent assay quantification of cytokine concentrations in human meningiomas. Neurosurgery 1996;39:823-828; discussion 828-829
232. Boyle-Walsh E, Hashim IA, Speirs V, Fraser WD, White MC. Interleukin-6 (IL-6) production and cell growth of cultured human ameningiomas: interactions with interleukin-1 beta (IL-1 beta) and interleukin-4 (IL-4) in vitro. Neurosci Lett 1994;170:129-132
233. Huttner A, Lei T, Fahlbusch R, Schrell W, Adams EF. Relationship between cAMP induced inhibition of human meningioma cell proliferation and autocrine secretion of interleukin-6. Life Sci 1996;58:1323-1329
234. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96
235. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997;40:271-275
236. Zhang ZJ, Muhr C, Wang JL. Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells. Anticancer Res 16:717-723
237. Wober-Bingol C, Wober C, Marosi C, Prayer D. Interferon-alfa-2b for meningioma. Lancet 1995;345:331
238. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 2001;7:2269-2276
239. Gibelli N, Zibera C, Butti G, et al. Hormonal modulation of brain tumour growth: a cell culture study. Acta Neurochir (Wien) 1989;101:129-133.
240. Lee LS, Chi CW, Chang TJ, Chou MD, Liu HC, Liu TY. Steroid hormone receptors in meningiomas of Chinese patients. Neurosurgery 1989;25:541-545
241. Yu ZY, Wrange O, Boethius J, Hatam A, Granholm L, Gustafsson JA. A study of glucocorticoid receptors in intracranial tumors. J Neurosurg 1981;55:757-760
242. Carroll RS, Zhang J, Dashner K, Sar M, Wilson EM, Black PM. Androgen receptor expression in meningiomas. J Neurosurg 1995;82:453-460
243. Mailleux P, Przedborski S, Beaumont A, et al. Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas. Peptides 1990;11:1245-1253
244. Przedborski S, Levivier M, Cadet JL. Neurotensin receptors in human meningiomas. Ann Neurol 1991;30:650-654
245. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 1990;72:941-945
246. Battaini F, Leggio A, Govoni S, et al. Decrease in phorbol ester receptors in human brain tumors. Eur Neurol 1990;30: 241-246
247. Rudling MJ, Angelin B, Peterson CO, Collins VP. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 1990;50:483-487
248. Sawaya R, Yamamoto M, Ramo OJ, Shi ML, Rayford A, Rao JS. Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis. Neurosurgery 1995; 36:375-380; discussion 380-381
249. Shinoura N, Heffelfinger SC, Miller M, et al. RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett 1994;86:143-149
250. Figarella-Branger D, Pellissier JF, Bouillot P, et al. Expression of neural cell-adhesion molecule isoforms and epithelial cadherin adhesion molecules in 47 human meningiomas: correlation with clinical and morphological data. Mod Pathol 1994;7:752-761
251. Yamashima T, Sakuda K, Tohma Y, et al. Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process. J Neurosci 1997;17:2376-2382